Filing Details
- Accession Number:
- 0001179110-17-008246
- Form Type:
- 4/A
- Zero Holdings:
- No
- Publication Time:
- 2017-05-31 15:31:53
- Reporting Period:
- 2017-05-25
- Filing Date:
- 2017-05-31
- Accepted Time:
- 2017-05-31 15:31:53
- Original Submission Date:
- 2017-05-26
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1371217 | Enteromedics Inc | ETRM | () | 4/A |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1110780 | Carl Goldfischer | 2800 Patton Road St. Paul MN 55113 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2017-05-25 | 4,571 | $4.85 | 0 | No | 4 | S | Indirect | See footnote. |
| Common Stock | Disposition | 2017-05-25 | 97 | $4.85 | 0 | No | 4 | S | Indirect | See footnote. |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Indirect | See footnote. |
| No | 4 | S | Indirect | See footnote. |
Footnotes
- The price reported is the weighted average sale price for the transactions reported. The prices received ranged from $4.75 to $5.00. The Reporting Person will provide to the issuer, a security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range.
- This amendment is filed to correct the transaction code to note that shares sold were disposed of rather than acquired.
- Represents shares held by Bay City Capital Fund IV, L.P. ("Fund IV"), including the shares held by Dr. Goldfischer; and indirect interests of Bay City Capital LLC ("BCC"), the manager of Bay City Capital Management IV LLC ("Management IV"), and Management IV, the general partner of Fund IV. Dr. Goldfischer is Managing Director of BCC. Dr. Goldfischer, BCC and Management IV each disclaims beneficial ownership in such shares, except to the extent of their pecuniary interest therein.
- Represents shares held by Bay City Capital Fund IV Co-Investment Fund, L.P. ("Co-Investment IV"), including the shares held by Dr. Goldfischer; and indirect interests of BCC, the manager of Management IV, and Management IV, the general partner of Co-Investment IV. Dr. Goldfischer, BCC and Management IV each disclaims beneficial ownership in such shares, except to the extent of their pecuniary interest therein.
Billionaire Hedge Funds
